Drugs / Ga-68 labeled HBED-CC PSMA
Ga-68 labeled HBED-CC PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02611882 | Dec 2015 → Oct 2016 | prostate cancer | Thomas Hope | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga-68 labeled HBED-CC PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02611882 ↗ |
| Modality | Diagnostic / imaging agent | “The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68 HBED-CC PSMA)” NCT02611882 ↗ |
| Route | Intravenous | “It will be administered a single time intravenously prior to the PET/CT imaging.” NCT02611882 ↗ |